Semapimod

• Description :

  Semapimod, an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod inhibits TLR4 signaling (IC50≈0.3 μM) . Semapimod inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod has potential in a variety of inflammatory and autoimmune disorders[1][2][3].

• Product Name Alternative :

  CNI-1493 (free base) ; CPSI-2364

• UNSPSC :

  12352005

• Target :

  Interleukin Related; p38 MAPK; TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/semapimod.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC1=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C1)CCCCCCCCC(NC2=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C2)=O

• Molecular Formula :

  C34H52N18O2

• Molecular Weight :

  744.90

• References & Citations :

  [1]Nishimatsu H, et al. Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats. Hypertens Res. 2008;31 (4) :737‐743.|[2]Wang J, et al. Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone gp96. J Immunol. 2016;196 (12) :5130‐5137.|[3]Wehner S, Set al. Inhibition of p38 mitogen-activated protein kinase pathway as prophylaxis of postoperative ileus in mice. Gastroenterology. 2009;136 (2) :619‐629.|[4]Miller IS, et al. Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS One. 2014 May 9;9 (5) :e95885.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  IL-1; IL-6; p38 MAPK; TNFRSF5/CD40

• CAS Number :

  [352513-83-8]